Compare ORMP & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ORMP | CTMX |
|---|---|---|
| Founded | 2002 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 104.6M | 596.2M |
| IPO Year | N/A | 2015 |
| Metric | ORMP | CTMX |
|---|---|---|
| Price | $2.99 | $3.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $6.50 |
| AVG Volume (30 Days) | 226.0K | ★ 2.3M |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 838.25 | 50.22 |
| EPS | ★ 1.03 | 0.24 |
| Revenue | $2,000,000.00 | ★ $113,631,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $2.90 | $16.20 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.82 | $0.40 |
| 52 Week High | $3.20 | $4.62 |
| Indicator | ORMP | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 66.16 | 48.63 |
| Support Level | $2.66 | $3.78 |
| Resistance Level | $3.19 | $4.37 |
| Average True Range (ATR) | 0.13 | 0.26 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 61.12 | 33.57 |
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.